The hematopoietic stem cell transplantation market size was valued at USD 3.74 billion in 2025 and estimated to grow from USD 4.13 billion in 2026 to reach USD 6.83 billion by 2031, at a CAGR of 10.55% during the forecast period (2026-2031). This report Segments the Industry Into by Transplant Type (Autologous Transplant, and More), Stem Cell Source (Peripheral Blood Stem Cell Transplant, and More), Indication (Leukemia, and More), End User (Transplant & Cellular-Therapy Centers, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).
Momentum is also evident in haploidentical protocols, where partial matches from relatives expand donor pools and reduce search times. A Johns Hopkins study documented 95% overall survival and 88% cure rates in sickle-cell disease using reduced-intensity, haploidentical bone-marrow transplantation. These outcomes reinforce the competitive edge of allogeneic grafts even as autologous approaches face substitution risk from CAR-T therapies. The Hematopoietic stem cells transplantation market therefore remains anchored by allogeneic innovation, with process automation and targeted conditioning poised to enhance margin profiles.
Peripheral-blood procedures retained 80.62% share of the Hematopoietic stem cells transplantation market in 2025 due to rapid engraftment and donor convenience. Growth, however, is tilting toward cord-blood transplants, which are advancing at a 12.15% CAGR. The 2024 Omisirge approval shortened median neutrophil recovery to 12 days from 22 days for standard cord units, proving commercial viability for expanded grafts.
China has performed nearly 40,000 therapeutic cord-blood infusions, including 900 thalassemia transplants with 99% survival, illustrating how large-scale cord banking can propel the Hematopoietic stem cells transplantation market. Haplo-cord combinations now merge partial sibling grafts with cord units to solve cell-dose limitations in adults. Bone-marrow harvests remain relevant for indications requiring heightened graft-versus-leukemia effects, although their share continues to decline. Next-generation expansion platforms such as UM171 may further de-risk cord-blood usage in heavier patients.
Europe follows closely, backed by standardized EBMT guidelines and cross-border donor coordination. Adoption of treosulfan conditioning in Germany and Italy demonstrates how regulatory convergence accelerates technology diffusion. However, tighter budget caps in certain markets slow procedure growth compared with North America.
Asia-Pacific stands out with a 14.85% CAGR and is quickly narrowing the procedural-density gap. China’s National Health Commission has increased public funding for transplant infrastructure, while India introduced bundled-payment pilots that include long-term follow-up. New cord-blood labs in the United Arab Emirates rose from 2 to 8 after regulatory changes in 2020, showing how policy shifts can fast-track capacity. South America and the Middle East & Africa remain nascent but are positioned for double-digit growth as insurance coverage widens. Combined, these regional dynamics underscore the strategic importance of geographical diversity for companies targeting the Hematopoietic stem cells transplantation market.
Global Hematopoietic Stem Cell Transplantation Market Trends and Insights
Rising Global Incidence of Hematologic Malignancies
Cancer incidence reached 20 million new cases worldwide in 2024, and leukemias generate 34.65% of transplant procedures, reinforcing steady demand for the Hematopoietic stem cells transplantation market. Earlier detection protocols and Medicare’s 2024 coverage expansion for myelodysplastic syndromes have lowered access barriers in the United States. An aging population in Europe and North America sustains a large eligible pool, and emerging markets are following suit as diagnostic infrastructures improve. Screening at earlier disease stages supports better conditioning-tolerance windows, enabling more transplants. Given the constant rise in disease incidence, this driver is expected to keep momentum beyond 2030.Advancements in Conditioning Regimens
The January 2025 approval of treosulfan-based Grafapex enabled reduced-intensity conditioning with improved overall survival versus busulfan protocols, broadening the Hematopoietic stem cells transplantation market to frail or elderly patients. Precision pharmacogenomic testing now personalizes dosing and reduces organ toxicity. AI-directed regimen selection further lowers treatment-related mortality. Ongoing clinical programs are evaluating antibody-drug conjugate conditioning that targets malignant cells while sparing healthy tissue. Collectively, these innovations enlarge the candidate pool and cut inpatient lengths of stay.High Cost of HSCT Procedures and Long-Term Post-Transplant Care
Total episode spending often exceeds USD 400,000, straining both payers and patients. Proposed Medicare payment reforms now tie reimbursement to measurable outcomes, but uniform implementation remains elusive. Chronic graft-versus-host disease adds 50% to hospitalization expenses, with mean inpatient costs in the United Kingdom hitting GBP 18,567 in 2024. Emerging value-based contracts cover only a fraction of transplant centers, slowing widespread adoption. Financial toxicity is therefore likely to limit adoption in health systems with constrained budgets.Other drivers and restraints analyzed in the detailed report include:
- Increased Investment in Regenerative Medicine and Cell Therapy R&D
- Expansion of International Donor Registries and HLA-Typing Technologies
- Limited Availability of Matched Donors
Segment Analysis
Allogeneic procedures captured 57.84% of the Hematopoietic stem cells transplantation market in 2025 and are tracking an 11.05% CAGR to 2031, signaling enduring reliance on donor-sourced grafts. Orca-T posted superior Phase 3 survival and relapse outcomes versus standard care and showcases how selective graft engineering can cut graft-versus-host disease, further enlarging adoption. The segment benefits from registry growth, improved HLA-typing accuracy, and prophylaxis innovations like post-transplant cyclophosphamide.Momentum is also evident in haploidentical protocols, where partial matches from relatives expand donor pools and reduce search times. A Johns Hopkins study documented 95% overall survival and 88% cure rates in sickle-cell disease using reduced-intensity, haploidentical bone-marrow transplantation. These outcomes reinforce the competitive edge of allogeneic grafts even as autologous approaches face substitution risk from CAR-T therapies. The Hematopoietic stem cells transplantation market therefore remains anchored by allogeneic innovation, with process automation and targeted conditioning poised to enhance margin profiles.
Peripheral-blood procedures retained 80.62% share of the Hematopoietic stem cells transplantation market in 2025 due to rapid engraftment and donor convenience. Growth, however, is tilting toward cord-blood transplants, which are advancing at a 12.15% CAGR. The 2024 Omisirge approval shortened median neutrophil recovery to 12 days from 22 days for standard cord units, proving commercial viability for expanded grafts.
China has performed nearly 40,000 therapeutic cord-blood infusions, including 900 thalassemia transplants with 99% survival, illustrating how large-scale cord banking can propel the Hematopoietic stem cells transplantation market. Haplo-cord combinations now merge partial sibling grafts with cord units to solve cell-dose limitations in adults. Bone-marrow harvests remain relevant for indications requiring heightened graft-versus-leukemia effects, although their share continues to decline. Next-generation expansion platforms such as UM171 may further de-risk cord-blood usage in heavier patients.
Complete Report Scope:
- By Transplant Type
- Autologous Transplant
- Allogeneic Transplant
- By Stem Cell Source
- Peripheral Blood Stem Cell Transplant
- Bone Marrow Transplant
- Cord Blood Transplant
- By Indication
- Leukemia
- Lymphoproliferative Disorders
- Multiple Myeloma & Plasma-Cell Dyscrasias
- Non-Malignant Blood Disorders
- By End User
- Transplant & Cellular-Therapy Centers
- Academic and Research Institutes
- Multi-Specialty Hospitals & Clinics
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America controlled 41.35% of the Hematopoietic stem cells transplantation market in 2025 thanks to favorable reimbursement mechanisms, a dense transplant-center network, and continuous trial activity. Medicare’s alignment of transplant payments with Diagnosis-Related Group revisions has improved provider liquidity, encouraging volume growth. The region also accounts for a sizable portion of global autologous transplants because of multiple myeloma prevalence.Europe follows closely, backed by standardized EBMT guidelines and cross-border donor coordination. Adoption of treosulfan conditioning in Germany and Italy demonstrates how regulatory convergence accelerates technology diffusion. However, tighter budget caps in certain markets slow procedure growth compared with North America.
Asia-Pacific stands out with a 14.85% CAGR and is quickly narrowing the procedural-density gap. China’s National Health Commission has increased public funding for transplant infrastructure, while India introduced bundled-payment pilots that include long-term follow-up. New cord-blood labs in the United Arab Emirates rose from 2 to 8 after regulatory changes in 2020, showing how policy shifts can fast-track capacity. South America and the Middle East & Africa remain nascent but are positioned for double-digit growth as insurance coverage widens. Combined, these regional dynamics underscore the strategic importance of geographical diversity for companies targeting the Hematopoietic stem cells transplantation market.
List of Companies Covered in this Report:
- Talaris Therapeutics
- Thermo Fisher Scientific
- Stem Cell Technologies
- Pluristem Therapeutics
- Merck
- Lonza Group
- Sartorius CellGenix
- ScienCell Research Laboratories
- ThermoGenesis Holdings
- Novartis
- Bristol-Myers Squibb
- Gilead Sciences
- Sanofi
- Takeda Pharmaceuticals
- GAMIDA Cell
- Bluebird bio
- Miltenyi Biotec
- Fujifilm Cellular Dynamics
- Cryoport Systems
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value in USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Talaris Therapeutics
- Thermo Fisher Scientific
- STEMCELL Technologies
- Pluristem Therapeutics
- Merck KGaA
- Lonza Group
- Sartorius CellGenix
- ScienCell Research Laboratories
- ThermoGenesis Holdings
- Novartis AG
- Bristol Myers Squibb
- Gilead Sciences
- Sanofi S.A.
- Takeda
- GAMIDA Cell
- Bluebird bio
- Miltenyi Biotec
- Fujifilm Cellular Dynamics
- Cryoport Systems
